

Special Issue

Personalized Approaches for the Prevention and Treatment of Breast Cancer

Message from the Guest Editor

Thanks to advances in our understanding of cancer biology, breast cancer is now recognized as more than one disease, which has been instrumental in the development of tailored therapeutic strategies in patients with breast cancer, including endocrine and targeted therapies and maybe soon immunotherapy. However, primary or acquired resistances to these therapies are a major clinical obstacle, with a significant proportion of breast cancer patients experiencing disease progression and death while taking these medications. Progress in genomics and the advent of new sequencing technologies have also paved the way for personalized approaches to early detection or prevention of breast cancer, even though their implementation at a population level faces considerable challenges. This Special Issue of the *Journal of Personalized Medicine* welcomes manuscripts focusing on personalized approaches relevant to breast cancer detection, diagnosis, treatment, and survivorship. The types of studies or perspectives expected include clinical, population-based, and interventional studies as well as ethical, social, legal, and economic analyses.


Guest Editor

Prof. Dr. Hermann Nabi

Department of Social and Preventive Medicine, Faculty of Medicine,
Laval University, Québec, QC G1V 0A6, Canada

Deadline for manuscript submissions

closed (20 March 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/71735

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).